Results 141 to 150 of about 3,601 (174)

Cell Cycle-Dependent Chronotoxicity of Irinotecan Hydrochloride in Mice

The Journal of Pharmacology and Experimental Therapeutics, 1997
The mechanisms underlying the circadian rhythm of the toxicity induced by irinotecan hydrochloride (CPT-11; 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin) were investigated from the viewpoint of the sensitivity of living organisms and the pharmacokinetics of the drug.
S, Ohdo, T, Makinosumi, T, Ishizaki, E, Yukawa, S, Higuchi, S, Nakano, N, Ogawa   +6 more
openaire   +2 more sources

Surface morphology control of polylactide microspheres enclosing irinotecan hydrochloride

International Journal of Pharmaceutics, 2005
In order to reduce the initial burst from polylactide (PLA) microspheres enclosing an antitumor agent, we prepared the microspheres with a smooth surface by varying solvent evaporation conditions such as operating temperature and pressure. PLA microspheres enclosing irinotecan hydrochloride (CPT) were prepared using the O/O emulsion system for solvent ...
Hidekazu, Yoshizawa, Satoru, Nishino, Koichiro, Shiomori, Shoji, Natsugoe, Takashi, Aiko, Yoshiro, Kitamura   +5 more
openaire   +2 more sources

Chemosensitivity Determinants of Irinotecan Hydrochloride in Hepatocellular Carcinoma Cell Lines

Basic & Clinical Pharmacology & Toxicology, 2008
Abstract:  Irinotecan hydrochloride (CPT‐11) is an effective anticancer drug, and its metabolic pathway has been well studied. Nevertheless, in human hepatocellular carcinoma (HCC), its cytotoxicity is less well studied and the determination of its chemosensitivity is unclear.
Takenori, Takahata, Keizou, Ookawa, Koji, Suto, Masanori, Tanaka, Hirohisa, Yano, Osamu, Nakashima, Masamichi, Kojiro, Yoshihiro, Tamura, Tomonori, Tateishi, Yuh, Sakata, Shinsaku, Fukuda   +10 more
openaire   +2 more sources

ChemInform Abstract: Synthesis of CPT‐11 (Irinotecan Hydrochloride Trihydrate)

ChemInform, 1997
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
S. SAWADA, T. YOKOKURA
openaire   +1 more source

[Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles].

Yao xue xue bao = Acta pharmaceutica Sinica, 2016
To investigate the pharmacokinetics of irinotecan hydrochloride (CPT-11) in rats and the tissue distribution of CPT-11 in mice after injection of irinotecan hydrochloride nanoparticles (CPT-11 NPs) via tail veins, separately, a LC-MS/MS method was established to determine the concentration of CPT-11 in whole blood of rats and in different tissues of ...
Fu-Ying, Yang, Wen-Ping, Zhang, He-Li, Chen, Yan, Fu, Xin-Yu, Wang, Shi-Jie, Wei, Xiao-Ying, Yang, Yu-Xin, Zhang, Hong-Wan, Dang   +8 more
openaire   +1 more source

[Irinotecan hydrochloride (CPT-11)].

Gan to kagaku ryoho. Cancer & chemotherapy, 1994
Irinotecan hydrochloride (CPT-11) is a water-soluble semisynthetic derivative of camptothecin. CPT-11 is a prodrug that undergoes deesterification in vivo to produce SN-38, a metabolite that is 1,000-fold more potent than the parent compound in vitro. CPT-11 is a potent topoisomerase I inhibitor with a broad spectrum of experimental antitumor activity.
openaire   +1 more source

Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated y-site administration.

International journal of pharmaceutical compounding, 2015
The objective of this study was to evaluate the physical and chemical stabilty of undiluted palonosetron hydrochloride 50 micrograms/mL in combination with topotecan hydrochloride 0.1 mg/mL or irinotecan hydrochloride 1 mg/mL in 5% dextrose injection during simulated Y-site administration.
Lawrence A, Trissel, Quanyun A, Xu
openaire   +1 more source

Irinotecan Hydrochloride (Conventional)

2022
Michelle C. Simpson, Eric G. Schaefer
openaire   +1 more source

[Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].

Gan to kagaku ryoho. Cancer & chemotherapy, 2002
A Phase I trial of irinotecan hydrochloride (CPT-11) was performed to determine the maximum tolerated dose (MTD), the dose-limiting toxicities, and the incidence and severity of other toxicities in children with advanced neuroblastoma. Three children received 11 courses of CPT-11 administered as a 90-min i.v.
T, Hirota, N, Kawai, S, Kitagawa, T, Hori, K, Konno, K, Sawada, H, Agata, T, Fujimoto, M, Tsurusawa   +8 more
openaire   +1 more source

Irinotecan Hydrochloride Injection

2021
openaire   +1 more source